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Abstract Alzheimer’s disease (AD) is characterized by the
presence of amyloid plaques mainly consisting of hydropho-
bic β-amyloid peptide (Aβ) aggregates and neurofibrillary
tangles (NFTs) composed principally of hyperphosphorylated
tau. Aβ oligomers have been described as the earliest effectors
to negatively affect synaptic structure and plasticity in the
affected brains, and cellular prion protein (PrPC) has been
proposed as receptor for these oligomers. The most widely
accepted theory holds that the toxic effects of Aβ are upstream
of change in tau, a neuronal microtubule-associated protein
that promotes the polymerization and stabilization of micro-
tubules. However, tau is considered decisive for the progres-
sion of neurodegeneration, and, indeed, tau pathology
correlates well with clinical symptoms such as dementia.
Different pathways can lead to abnormal phosphorylation,
and, as a consequence, tau aggregates into paired helical
filaments (PHF) and later on into NFTs. Reported data suggest
a regulatory tendency of PrPC expression in the development
of AD, and a putative relationship between PrPC and tau
processing is emerging. However, the role of tau/PrPC inter-
action in AD is poorly understood. In this study, we show
increased susceptibility to Aβ-derived diffusible ligands
(ADDLs) in neuronal primary cultures from PrPC knockout
mice, compared to wild-type, which correlates with increased
tau expression. Moreover, we found increased PrPC expres-
sion that paralleled with tau at early ages in an AD murine
model and in early Braak stages of AD in affected individuals.
Taken together, these results suggest a protective role for PrPC
in AD by downregulating tau expression, and they point to
this protein as being crucial in the molecular events that lead to
neurodegeneration in AD.
Keywords Alzheimer’s disease .Microtubule-associated
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Introduction
T h e c e l l u l a r p r i o n p r o t e i n ( P r P C ) i s a
glycosylphosphatidylinositol (GPI)-anchored cell surface pro-
tein highly expressed by neurons and glial cells in the adult
central nervous system (CNS) [1–3]. Its physiological func-
tions are poorly understood but a relation between the protein
and neuroprotection has been reported [4]. The abnormal
processing of PrPC gives rise to a proteinase-k-resistant
misfolded isoform termed PrPSC, which is the etiologic agent
of transmissible spongiform encephalopathies (TSEs) [5].
These encephalopathies are characterized by profound histo-
logical changes, including extensive neuronal death, reactive
Electronic supplementary material The online version of this article
(doi:10.1007/s12035-014-8793-7) contains supplementary material,
which is available to authorized users.
C. Vergara : J. A. del Río : R. Gavín (*)
Molecular and Cellular Neurobiotechnology, Institute for
Bioengineering of Catalonia, Baldiri Reixac 15-21, 08028 Barcelona,
Spain
e-mail: rgavin@ub.edu
C. Vergara : L. Ordóñez-Gutiérrez : F. Wandosell : I. Ferrer :
J. A. del Río : R. Gavín
Centro de Investigación Biomédica en Red sobre Enfermedades
Neurodegenerativas (CIBERNED), Madrid, Spain
J. A. del Río : R. Gavín
Department of Cell Biology, Faculty of Biology, University of
Barcelona, Barcelona, Spain
L. Ordóñez-Gutiérrez : F. Wandosell
Centro de Biología Molecular Severo Ochoa, Cabrera 1,
CBM-UAM, Madrid, Spain
I. Ferrer
Institute of Neuropathology, IDIBELL-Hospital Universitari de
Bellvitge, Faculty of Medicine, University of Barcelona, Hospitalet
de Llobregat, Spain
Mol Neurobiol (2015) 51:1206–1220
DOI 10.1007/s12035-014-8793-7
gliosis, and neuroinflammation, together with the extracellular
accumulation of aggregated PrPSC in affected brains [6, 7].
As with prionopathies, the most prevalent neurodegen-
erative dementia, Alzheimer’s disease (AD), presents ex-
tracellular deposition of an abnormally processed protein,
the amyloid precursor protein (APP). Individuals suffering
AD are characterized by a progressive cognitive decline
and behavioral changes, and the main neuropathological
hallmarks include the presence of senile plaques, enriched
in β - amylo id (Aβ ) pep t ide , and in t r a ce l l u l a r
hyperphosphorylated tau protein which aggregates in neu-
rofibrillary tangles (NFTs) (e.g., [8, 9]). Tau is a neuronal
microtubule-associated protein that promotes the polymer-
ization and stabilization of microtubules [10] under the
regulatory control of several kinases and phosphatases. In
this sense, glycogen synthase kinase 3 (GSK3β) and the
cyclin-dependent kinase 5 (Cdk5) are the main kinases
implicated in the phosphorylation of some tau epitopes
observed in AD [11–14]. When hyperphosphorylated, tau
detaches from microtubules, leading to increased instabil-
ity, impaired axonal transport, and profound deficits in
synaptic function. In fact, today, it is recognized that some
of the kinases misregulated in AD (e.g., GSK3β) affect
both Aβ production [15] and tau hyperphosphorylation
[16].
Several TSEs show an abnormal processing of tau protein,
in parallel to the presence of PrPSC. In fact, increased levels of
tau protein have been detected in the cerebrospinal fluid (CSF)
and serum of Creutzfeldt-Jakob’s disease (CJD) patients [17,
18]. In parallel, Wang and coworkers have described several
changes in expression and phosphorylation levels of tau in
infected hamsters. This occurs in parallel with the alteration of
Cdk5 and GSK3 transcription levels [19]. In addition, other
studies have associated GSK3β and Cdk5 activity with neu-
rotoxic processes induced by the PrP(106–126) peptide, a syn-
thetic peptide widely used as a model of neurotoxicity in prion
research (e.g., [20, 21]). In parallel, PrPC may bind with
several intracellular proteins including tubulin [22, 23]. And,
more relevantly, Wang et al. described physical interaction
between tau and PrPC hypothesizing that the presence of
phosphorylated tau in some TSEs is the result of a differential
affinity between tau and the N-terminal octarepeat (OR) do-
main of PrPC [24]. Moreover, the PrPC mutation associated
with Gerstmann-Sträussler-Scheinker syndrome (GSS),
P102L, resulting in an increased number of ORs, shows
greater tau interaction [25]. Taken together, these observations
suggest a role for PrPC in tau changes related to TSEs.
The widely accepted amyloid cascade hypothesis posits
that the deposition of Aβ in the brain parenchyma triggers a
sequence of events leading to tau dysfunction [26, 27]. In this
sense, Lambert and coworkers attributed higher toxic potential
to Aβ-derived diffusible ligands (ADDLs) than to insoluble
forms of Aβ [28]. ADDL treatment is proapoptotic, inducing
synaptic alterations and interfering with long-term potentia-
tion [29, 30]. Lauren and coworkers point to PrPC as being
responsible for this phenomenon [31]. In this sense, transgenic
ADmouse models require endogenous PrPC to induce several
deficits in learning and memory [32]. The effect of deleting
PrPC on mouse transgene phenotypes is similar to that of
deleting tau expression, with a lessening of Aβ neuronal
dysfunction in both cases [33]. At nanomolar concentrations,
neurotoxicity of ADDLs depends on membrane receptors and
in turn on the kinase Fyn, which induces the recruitment of
oligomers in “lipid rafts” of plasma membrane [34]. Both
PrPC and tau are localized in these membrane microdomains
[35]. In parallel, antibody-mediated aggregation of PrPC on
the cellular surface activates Fyn and other kinases in vitro
initiating a signaling transduction cascade that induces tau
phosphorylation in tyr18, an epitope implicated in AD
[36–38]. In this scenario, several studies have suggested that
oligomeric Aβ cytotoxicity in AD depends on the level of tau
[39] and is mediated by PrPC, which in turn promotes the
activation of Fyn and the consequent hyperphosphorylated tau
[40–42].
Additionally, several studies have reported changes in PrPC
expression in aging and in the development of AD. Higher
PrPC levels have been described in old healthy mice compared
with younger animals [43]. Moreover, decreased expression
of PrPC in AD cases [43] with increased levels at the start of
the disease and in other neurodegenerative disorders [44, 45]
has been also reported. A recent study has shown regulation of
Aβ production by the prion protein [46]. Taken together, these
observations suggest a protective role for PrPC in AD rein-
forcing the hypothesis regarding a neuroprotective function of
the protein [4]. Taking into account the physical interaction
between PrPC and both ADDL and tau, we investigated the
role of the tau/PrPC relationship in the phatogenic cascade of
AD, and our results indicate that PrPC plays an important role
in the molecular events that lead to neurodegeneration in AD,
by regulating total tau levels.
Material and Methods
Mouse Strains and Genotyping
We used four transgenic mouse lines at different ages. In
addition, embryos from pregnant females of the different
genotypes were also used. Mating day was considered to be
embryonic day 0 (E0) and the offspring was genotyped ac-
cording to the genotype of the crossed progenitor.
Prnp0/0 mice bred from a C57BL6J/129, Ola/Sv back-
ground [47] were purchased from EMMA (Monterotondo,
Italy). We backcrossed to C57BL/6 J for at least 15 genera-
tions to obtain Prnp0/0 and control littermates Prnp+/+. Nine
adult mice and 17 pregnant females were used in this study.
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Specific primers to Prnp genotyping were designed in our
laboratory based on the original P3 and P10 primers as de-
scribed [47]: neo: 5′-gccttctatcgccttcttgac-3′; 3′NCnew: 5′-
g c t a c a g g t g g a t a a c c c c t c - 3 ′ a n d P 1 0 n ew : 5 ′ -
cataatcagtggaacaagccc-3′. The 40 cycling conditions were
95 °C for 45 s, 62 °C for 45 s, and 72 °C for 1 min, followed
by a final extension at 72 °C for 5 min.
Prnp-overexpressing mice (Tg20) were purchased from
EMMA. They were generated from Prnp0/0 mice as described
by Fischer et al. [48]. Eleven pregnant females were used in
this study. For Tg20mice, the transgene was detected by using
p r i m e r s s p e c i f i c t o t h e T g 2 0 a l l e l e s 5 ′ -
c a a c c g a c g t g a a g c a t t c t g c c t a - 3 ′ a n d 5 ′ -
cctgggactccttctggtaccgggtgacgc-3′ as indicated [49].
APP/PS1 transgenic mouse line expresses human APP
Swedish, and presenilin 1 deleted in exon 9 mutations, and
is named B6.Cg-Tg (APPSwe, PSEN1dE9). These mice were
purchased from Jackson Laboratory (Bar Harbor, ME, USA).
We used 13 transgenic mice and non-transgenic littermates as
controls for each age. Also, 14 pregnant females were used in
this study. Mice were genotyped as by Jankowsky [50] using
three primers; one antisense primer matching sequence within
PrPC (5′-gtggataccccctcccccagcctagacc-3′), one sense primer
specific to the transgene (PS1: 5′-caggtggtggagcaagatg-3′ or
APP: 5′-ccgagatctctgaagtgaagatggatg-3′), and a third sense
p r i m e r s p e c i f i c t o t h e g e n om i c P r P C ( 5 ′ -
cctctttgtgactatgtggactgatgtcgg-3′).
TgTP6.3 mouse line is a transgenic mouse carrying a tau-
tagged green fluorescence protein (GFP) transgene generated
by Pratt et al. [51]. Mice carrying the tau-GFP transgene were
identified by fluorescence microscopy of tail tissue. Three
adult mice were used in this study.
All experiments were performed under the guidelines
and protocols of the Ethical Committee for Animal Ex-
perimentation (CEEA) at the University of Barcelona, and
the protocol for the use of animals in this study was
reviewed and approved by the CEEA at the University
of Barcelona (CEEA approval# 115/11).
Human Cases
Human cases comprise 6 non-AD and 31 AD postmortem
brains from the Institute of Neuropathology and University of
Barcelona/Hospital Clinic Brain Banks. All brains were ob-
tained following the Code of Ethics of the World Medical
Association and the protocols of the local Ethical Committee.
Basic patient data are shown in Table 1. Cases with and
without clinical neurological disease were processed in the
same way following the same sampling and staining
protocols. At autopsy, half of each brain was fixed in 10 %
buffered formalin, while the other half was cut in coronal
sections 1 cm thick, frozen on dry ice, and stored at −80 °C
until use. In addition, 2-mm-thick samples of the cerebral
isocortex, cingulum, hippocampus and entorhinal cortex,
and brainstem were fixed with phosphate-buffered 4 % para-
formaldehyde for 24 h, cryoprotected with 30 % sucrose,
frozen on dry ice, and stored at −80 °C until use.
Following neuropathological examination, AD cases were
categorized as stages I to VI of Braak and Braak [52, 8].
Healthy cases (non-AD) did not show neurological or meta-
bolic disease, and the neuropathological examination, carried
out in similar regions and with the same methods as in AD
cases, did not show lesions. In particular, no amyloid or tau
deposits were seen in the regions examined. The group is
represented by middle-aged adults because most individuals
over 65 years old might have preclinical signs of AD [53].
Table 1 Control and AD patients, categorized as stages I to VI of Braak
and Braak, used in this study
Case
number
Braak and
Braak stage
Gender Age Age
(mean±s.d.m)
Postmortem
delay
C1
C2
C3
C4
C5
C6
–
–
–
–
–
–
M
F
M
M
M
M
39
46
53
46
43
52
46.5±5.3 9 h 15 min
14 h 15 min
7 h 25 min
15 h
4 h 35 min
3 h
AD1
AD2
AD3
AD4
AD5
AD6
AD7
AD8
AD9
AD10
I
I
I
I
I
I
I
I
I
I
M
M
M
M
M
F
M
F
M
M
61
53
74
71
64
79
65
75
63
68
67.3±7.7 3 h 40 min
6 h 15 min
4 h
11 h 30 min
2 h 15 min
3 h 35 min
5 h 15 min
4 h 55 min
6 h
10 h 55 min
AD11
AD12
AD13
AD14
AD15
AD16
AD17
AD18
II
II
II
II
II
II
II
II
F
M
M
M
M
M
F
F
77
65
66
72
71
66
60
80
69.6±6.7 11 h
5 h
4 h 55 min
8 h 45 min
5 h 15 min
5 h
9 h 40 min
3 h 30 min
AD19
AD20
AD21
III
III
III
F
M
F
81
71
77
76.3±5.0 1 h 30 min
7 h 15 min
11 h 30 min
AD22
AD23
AD24
AD25
IV
IV
IV
IV
F
F
M
M
80
81
84
79
81±2.1 2 h 45 min
12 h
12 h 45 min
50 min
AD26
AD27
AD28
AD29
V
V
V
V
M
M
M
M
87
75
82
77
80.3±5.4 7 h 5 min
11 h 30 min
3 h 45 min
16 h
AD30
AD31
VI
VI
M
M
86
67
76.5±13.4 20 h 35 min
8 h
F female, M male
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Primary Embryonic Neuronal Cultures
E15-16 mouse embryo brains were dissected and washed in
ice-cold 0.1 M phosphate-buffered saline (PBS) containing
6.5 mg/ml glucose. The meninges were removed and the
cortical lobes isolated. Tissue pieces were trypsinized for
15 min at 37 °C. After addition of horse serum and then
centrifugation, cells were dissociated by trituration in 0.1 M
PBS containing 0.025 % DNase with a polished pipette (all
from Sigma, MO, USA). Dissociated cells were plated at
~3,000 cells/mm2 on plates (Nunc, Denmark) coated with
poly-D-lysine (Sigma). The culture medium was Neurobasal
supplemented with 2 mM glutamine, 6.5 mg/ml glucose,
antibiotics (Pen./Strept.), 5 % horse serum, and B27
(Invitrogen-Life Technologies, Belgium). After 72 h, AraC
5 μM (cytosine β-D-arabinofuranosidehydrochloride
(Sigma)) was added for 48 h to inhibit the growth of dividing
non-neuronal cells. Cultures were used after 7 days in vitro.
Treatment of Cortical Cultures with Aβ Peptides
Aβ1–42 peptide was purchased from Bachem (Bubendorf,
Switzerland). Different aliquots of Aβ1–42 were prepared as
described previously [54, 55] and stored desiccated at −80 °C.
To obtain soluble oligomers (ADDLs), a working solution of
100 μM was prepared in culture medium and incubated at
4 °C for 24 h to treat the cultures with a final concentration of
10 μM. For the fibril-forming conditions, we chose the acidic
pH method using 10 mM HCl with 24-h incubation at 37 °C,
and cultures were treated with a final concentration of 10 μM.
Peptide-treated cells were scraped in homogenization
buffer containing 50 mM Hepes, 150 mM NaCl, 1.5 mM
MgCl2, 1 mM EGTA, 10 % glycerol, 1 % Triton X-100,
and 1× protease inhibitor cocktail (Roche Diagnostic,
Switzerland) and 1 μM okadaic acid (Merck Millipore,
MA, USA), 0.1 M sodium fluoride, 10 mM sodium py-
rophosphate, and 1 mM sodium orthovanadate (Sigma) as
phosphatase inhibitors.
Transmission Electron Microscopy Procedures
For transmission electron microscopy (TEM), peptide solu-
tions incubated for 24 h for each condition, both in culture
medium at 4 °C and in 10 mM HCl at 37 °C, were fixed to
carbon-forward-coated copper supports. Negative staining
was performed using a 2 % uranyl acetate stain (pH 7.4)
(Sigma), after which samples were placed in silica-based
desiccant for a minimum of 2 h. Finally, we proceeded to
TEM observation using a Leica microscope (Wetzlar, Germa-
ny) at the Electron Microscopy Service, University of Barce-
lona, Barcelona, Spain.
Lentiviral Vector Production
Lentiviral particles were produced by transient transfection
of 293FT cells with Lipofectamine 2000 (Invitrogen-Life
Technologies) using Mission shRNA prion protein
NM_011170 (Sigma), the second-generation packaging
construct psPAX2 (Tronolab, Switzerland), and the enve-
lope plasmid pMD2G (Tronolab). 293FT cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen-Life Technologies) supplemented with 10 %
fetal calf serum (FCS) (Invitrogen-Life Technologies) and
without antibiotics before transfection. Medium was
changed and supplemented with antibiotics after 6 h. Vec-
tor supernatants containing viral particles were harvested
approximately 48 and 72 h later and concentrated by ultra-
centrifugation (2 h at 26,000 rpm at 4 °C, in an Optima
LK98, SW-28 rotor).
Western Blotting Techniques
Soluble extract from human hippocampal samples, mouse
cortex brains, and cultured cells were processed for west-
ern blot. The collected samples were homogenized in lysis
buffer: 50 mM Hepes, 150 mM NaCl, 1.5 mM MgCl2,
1 mM EGTA, 10 % glycerol, 1 % Triton X-100 or
100 mM Tris pH 7.0, 100 mM NaCl, 10 mM EDTA,
0.5 % NP-40, and 0.5 % sodium deoxycolate, and in both
cases with supplemental 1× protease inhibitor cocktail and
phosphatase inhibitors as indicated above. After this, sam-
ples were centrifuged at 13,000×g for 20 min at 4 °C.
The resulting supernatant was normalized for protein con-
tent using BCA kit (Pierce Biotechnology, USA). Cell
extracts were boiled in Laemmli sample buffer [56] at
96 °C for 5 min, followed by 10 % SDS-PAGE electro-
phoresis, and they were then electrotransferred to nitro-
cellulose membranes for 1 h at 4 °C. Membranes were
blocked with 5 % non-fat milk in 0.1 M Tris-buffered
saline (pH 7.4) for 2 h and incubated overnight in 0.5 %
blocking solution containing primary antibodies. After
incubation with peroxidase-tagged secondary antibodies
(1:2,000 diluted), membranes were revealed with the
ECL-plus chemi luminescence wes te rn b lo t k i t
(Amersham-GE Healthcare, UK).
In our experiments, each nitrocellulose membrane was
used to detect consecutive antigens. To perform this se-
quential incubation, membranes were incubated in 25 ml of
stripping solution (2 % SDS, 62.5 mM Tris pH 6.8, and
100 mM 2-mercaptoethanol) for 30 min at 65 °C and then
extensively washed before reincubation with blocking
buffer and antibodies for re-blotting. Some samples were
dephosphorylated using γ-phosphatase (New England
Biolabs, MA, USA) as described [57].
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Primary Antibodies
Several antibodies were used for immunohistochemistry and
western blot. To detect amyloid species, we used 6E10
(Covance, NJ, USA), which specifically recognizes the first
16 amino acids of the Aβ peptide. Monoclonal anti-PrP 6H4
(Prionics, Zurich, Switzerland) was used to determine PrPC
levels. Different phosphorylation sites of tau were checked
with anti-ptau thr181 (Signalway Antibody, MA, USA), anti-
ptau ser199/202 (pSpS) (Invitrogen-Life Technologies), anti-
ptau ser202 (AT8) (Thermo Scientific, MA, USA), and anti-
ptau ser396/404 (PHF-1), a gift from Peter Davies (Albert
Einstein College of Medicine, Bronx, New York, USA). Total
levels of the tau protein were checked with monoclonal tau 5
antibody (Invitrogen-Life Technologies). The monoclonal
anti-β-actin antibody (Merck Millipore) was used as internal
control in western blots.
Aβ(1-42) Quantification by ELISA
The brain homogenates obtained as described above were
diluted 1:50 in albumin-PBS-Tween buffer (5 % bovine
serum albumin, 0.03 % Tween 20 in PBS) before centri-
fugation (16,000×g for 20 min at 4 °C), and the super-
natant was used shortly after preparation. Brain amyloid
burden was measured using the Aβ42 Human ELISA kit
(Invitrogen-Life Technologies) following the manufac-
turer’s protocol. Microwell plate absorbance at 450 nm
was read with Opsys MR microplate reader (Dynex
Technologies, VA, USA).
RT-qPCR
Quantitative real-time PCR was performed on total RNA
extracted with mirVana’s isolation kit (Ambion, TX, USA)
from the cortex of analyzed mice or from cultured cells.
Purified RNAs were used to generate the corresponding
cDNAs, which served as PCR templates for messenger
RNA (mRNA) quantification. The primers used in this study
for RT-qPCR validation were 5′-ccccctaagtcaccatcagctagt-3′
and 5′-cactttgctcaggtccaccggc-3′ for mouse tau [58], and 5′-
agtcgttgccaaaatggatca-3′ and 5′-aaaaaccaacctcaagcatgtgg-3′
for mouse PrPC [59].
PCR amplification and detection were performed with
the ROCHE LightCycler 480 detector, using 2× SYBR
GREEN Master Mix (Roche) as reagent, following the
manufacturer’s instructions. The reaction profile was
denaturation-activation cycle (95 °C for 10 min) follow-
ed by 40 cycles of denaturation-annealing-extension
(95 °C for 10 s, 55 °C for 15 s, and 72 °C for 20 s).
mRNA levels were calculated using the LightCycler 480
software. Data were analyzed with SDS 1.9.1 Software
(Applied Biosystems, USA) following the 2-ΔΔCT method
of Applied Biosystems [60]. The results were normalized
by the expression levels of the housekeeping gene,
g a p d h ( 5 ′ - a g g t c g g t g t g a a c g g a t t t g - 3 ′ a n d 5 ′ -
tgtagaccatgtagttgaggtca-3′), which were quantified si-
multaneously with the target gene [61].
Immunohistochemical Procedures
For immunohistochemistry, postnatal mice were anesthe-
tized and perfused with 4 % paraformaldehyde (PFA) in
PBS pH 7.4. After perfusion, the brains were removed
and pos t f ixed in the same solu t ion for 12 h ,
cryoprotected in 30 % sucrose in PBS, and sectioned
(30 μm) on a freezing microtome (Leica). They were
then processed for the immunohistochemical detection
of Aβ, tau, and PrPC, respectively, following an
immunoperoxidase protocol. Briefly, free-floating sec-
tions from different developmental stages were proc-
essed in parallel. Sections were rinsed in 0.1 M PBS,
and endogenous peroxidase activity was blocked by in-
cubation in 3 % hydrogen peroxide (H2O2) and 10 %
methanol dissolved in 0.1 M PBS. For amyloid plaque
detection, tissue was incubated in 70 % formic acid for
30 min. After extensive rinsing, sections were incubated
in 0.1 M PBS containing 0.2 % gelatin, 10 % normal
goat serum, 0.2 % glycine, and 0.2 % Triton X-100, for
1 h at room temperature. Afterward, sections were incu-
bated for 36 h at 4 °C with primary antibodies. After
that, sections were incubated with the appropriate sec-
ondary biotinylated antibodies (2 h, 1:200 diluted) and
streptavidin-horseradish peroxidase complex (2 h, 1:400
diluted). Peroxidase activity was revealed with 0.025 %
diaminobenzidine (DAB) and 0.003 % H2O2. After rins-
ing, sections were mounted onto slides and dehydrated,
and coverslipped with EukittTM (Merck). Immunohisto-
chemical controls, including omission of the primary
antibody or its replacement by normal serum, were de-
void of staining. Images were obtained using an Olym-
pus BX61 microscope equipped with cooled DP72L dig-
ital camera.
Densitometry and Statistical Processing
For the quantification of western blots, developed
f i lms were scanned at 2 ,400 × 2,400 dpi ( i800
MICROTEK high-quality film scanner, Hsinchu, Tai-
wan), and the densitometric analysis was performed
using Quantity One Image Software Analysis (Biorad,
Barcelona, Spain). Statistical analysis of the resulting
data was performed using STATGRAPHICS Plus 5.1
and Origin 8™ programs using ANOVA test. Asterisks
in the histograms indicate the following p values of
significance: (*) p<0.05; (**) p<0.01.
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Results
Increased Susceptibility of Tau Phosphorylation to ADDLs
in Cortical Cultures Lacking PrPC
In vitro ADDL treatment led to hyperphosphorylated tau in
several residues as also occurs in the brain parenchyma of AD
patients [11, 62]. Indeed, although there were some contradic-
tory results (i.e., ser404 residue), these tau phospho-epitopes
have been largely reported [63, 64].
Initially we aimed to determine whether acute changes of
Prnp expression might affect cellular tau levels before ana-
lyzing levels of phosphorylated tau (ptau). Thus, primary
cultures from Prnp+/+, Prnp0/0, and Tg20 embryos were pre-
pared. In parallel, primary cultures from Prnp+/+ embryos
were treated with siRNA-PrPC. Western blot analysis indicat-
ed that tau levels remained constant in all three genotypes and
under silencing PrPC expression (data not shown). In addition,
further MAPT analysis of previously obtained microarray
results using neuroblastoma N2a cells [65] reinforced these
results showing constant tau levels in this cell line indepen-
dently of PrPC expression [65].
Next, to investigate whether PrPC expressionmodulates the
phosphorylation of tau induced by ADDL treatment, primary
cortical neurons from Prnp0/0, Prnp+/+, and Tg20 embryos
were incubated with 10 μMADDLs or vehicle alone for 3, 6,
and 24 h after 7 DIV (Fig. 1 and Supplementary Fig. S1d). In
all experiments, peptide aggregation prior to treatment was
corroborated both by western blot (Supplementary Fig. S1a)
and by transmission electron microscopy (TEM) observation
(Supplementary Fig. S1b) (see also “Material and Methods”
section for details). Densitometric analysis of revealed films
demonstrated that Prnp0/0 cortical neurons incubated with
ADDLs showed an increase in tau phosphorylation (phosho-
tau/total tau ratio) in all residues studied (ser396/404, ser202/
thr205, and thr181) (Fig. 1a, c) at 3 and especially at 6 h. In
contrast, no significant changes in tau phosphorylation were
found in cultured Prnp+/+ cells treated with ADDLs for 3 and
6 h (Fig. 1a, c). In addition, in cultured neurons from Tg20
mice incubated with ADDLs, there was no significant increase
in phosphorylation of the tau epitopes (ser396/404, ser202/thr205,
and thr181) when compared with Prnp+/+ cultures (Fig. 1b, c).
Synergistic Effect of Absence of PrPC and ADDLTreatment
in Tau Protein Levels in Cultured Neurons
Next, we aimed to determine whether there is an increase in
tau protein levels after ADDL treatment and its putative
relationship with the presence or absence of PrPC. Results
showed that after incubation of ADDLs, levels of tau (total
tau/actin ratio) increased by ~12 % at 3 h and ~23 % at 6 h
from treatment in Prnp0/0 cortical cultures (Fig. 1a, d). More-
over, an increase, although smaller, was observed in Tg20-
derived cortical cultures after ADDL treatment (~8 % at 3 h
and ~11 % at 6 h) (Fig. 1b, d). In parallel, PrPC levels showed
an increase at 3 and 6 h after ADDL treatment only when a
total tau increase was detected in Tg20 cultures (~15 % in-
crease at 3 h and ~24% increase at 6 h, respectively) (Fig. 1b).
More relevantly, both ptau and total tau levels were un-
changed after 24 h of ADDL treatment in these phenotypes
(Supplementary Fig. S1d). These data correlate with the ob-
servations that Aβ aggregated for 24 h was unable to induce
changes in tau levels (Supplementary Fig. S2) and that after
24 h in culture conditions (37 °C) ADDLs can form fibrils
(Supplementary Fig. S1c). Taking this into account, further
experiments were performed at 6 hours from ADDL
treatment.
Given that the tau 5 antibody recognizes both native and
phosphorylated forms of tau, some samples were dephosphor-
ylated after 6 h following ADDL treatment using γ-
phosphatase (see “Material and Methods” section for details)
and then analyzed with western blotting. Our results showed
an increase in total tau level independently of phosphoryla-
tion, suggesting that ADDLs cause an increase in tau expres-
sion (Fig. 1e), probably prior to hyperphosphorylation. More-
over, increased levels of tau in Prnp0/0 cultures treated with
ADDLs were also corroborated with RT-qPCR at 6 h (Fig. 1f).
To discriminate between putative differences in genetic
background of Prnp0/0 versus Tg20 [66] or differences due
to intrinsic levels of PrPC, we performed similar experiments
in Prnp+/+ treated with lentiviral vector neurons carrying a
small interfering RNA (siRNA) for Prnp (see “Material and
Methods” section for details). Cells infected with these lenti-
virus showed a 15–30 % decrease in PrPC expression accord-
ing to different experiments and compared with control cul-
tures infected with enhanced green fluorescent protein (GFP)-
encoding lentiviral particles. After exposure to ADDLs for
6 h, treated cultures showed a statistically significant ~14 %
increase in tau expression only when PrPC expression was
decreased (Fig. 1g). This finding suggests that a small de-
creased expression of PrPC is enough to compromise the
increased tau expression in the presence of ADDLs. Lastly,
we also stimulated cultured Prnp0/0 cells with both ADDLs
and/or Aβ fibers for 6 h to determine whether the increased
tau was associated exclusively with ADDLs. Indeed, our
results showed a significant increase in total tau levels with
western blot only in cortical Prnp0/0 cells treated with ADDLs
for 6 h (Supplementary Fig. S2). In conclusion, PrPC seems to
be a relevant factor in controlling tau levels after ADDL
treatment.
Parallel Progression of PrPC and Tau Expression in APP/PS1
Mice
Several studies have reported progressive development of
AD-like pathology in an APP/PS1 mouse model including
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both Aβ deposition at 4 months and the presence of
hyperphosphorylated tau in affected neurons at 6 months of
age (e.g., [67, 68]). First, we analyzed the presence of amyloid
plaques in the APP/PS1 model and amyloid burden in our
Fig. 1 Analysis of effect of ADDLs on tau. a, b Cortical cultures from
Prnp0/0 or PrnP+/+ mice (a) and Tg20 mice (b) were treated with either
ADDL (10 μM) (n=6 Prnp0/0, n=6 PrnP+/+, and n=6 Tg20) or vehicle
alone for 3 and 6 h (n=6 Prnp0/0, n=6 PrnP+/+, and n=6 Tg20; each
case). Samples were analyzed with western blot using different anti-
phospho-tau or total tau antibodies in parallel with anti-PrPC antibody
to reveal PrPC expression in each sample. Membranes were retested with
an antibody against actin for normalization. c Densitometric analysis
showing the increase in phosphorylated tau levels (epitopes ser396/404,
ser202/thr205, and thr181, respectively) only inPrnp0/0 mouse samples after
3 or 6 h of ADDL treatment when compared to the vehicle control. d
Densitometric analysis showing the increase in total tau levels only in
Prnp0/0 mouse samples at 3 and 6 h posttreatment and the slight increase
in total tau levels in Tg20 mice at the same time of stimuli. Data on tau-
phosphorylated and total tau protein levels in control samples (vehicle
alone) were considered as the unit at each experimental time, and the rest
of the data were corrected as an increase of this initial value. e, fAnalysis
of tau expression in protein extracts of cortical Prnp0/0 cultures treated
with ADDLs for 6 h after treatment with λ-phosphatase with western blot
(e) (n=4) or analyzed by RT-qPCR (n=3) (f). Densitometric values in e
are standardized with vehicle treatment, and quantification was represent-
ed as fold increase±SEM. g Neuronal primary cultures from wild-type
mice were also stimulated in the same conditions after silencing PrPC
expression with a lentivirus. The western blot analysis showed an in-
crease in tau expression only in the silenced ones comparedwith the wild-
type ones. Densitometric values in c, d, and f are standardized with
vehicle treatment, and quantification was represented as fold change±
SEM. Bars represent the mean of three independent experiments.
*p<0.05, **p<0.01 (ANOVA test)
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mouse colony (Supplementary Fig. S3). Increased levels of
Aβ could be detected in our APP/PS1 Tg mice at 3 months of
age, and increasing numbers of plaques were observed in the
cerebral cortex from 4 to 9 months (Supplementary Fig. S3).
Next, we aimed to analyze the correlation among tau phos-
phorylation, total tau levels, and PrPC expression in the cere-
bral cortex of APP/PS1 Tg mice at different postnatal ages (3,
6, and 9 months) using immunohistochemistry and western
blot (Fig. 2). The immunohistochemical results showed an
increase in total tau immunoreactivity (Fig. 2b) in correlation
with higher PrPC expression (Fig. 2d) in 3-month-old trans-
genic mice when compared with wild-type (Fig. 2a, c, respec-
tively). This correlates with western blot results (Fig. 2e).
Densitometric analysis of developed films showed a ~13 %
increase in total tau levels of 3-month-old Tg APP/PS1 with
respect to non-transgenic mice (Fig. 2e, f) and a correlated
~16 % increase in PrPC levels in the same animals (Fig. 2e, g).
This increase of tau and PrPC was not observed at 6 and
9months of age. Then, analysis of phosphorylation for several
tau epitopes (ser396/404, ser202/thr205, and thr181) was per-
formed in the same animals by western blot. Our results
showed non-significant increase in phospo-tau/total tau ratio
for any residue studied (Fig. 2e). Data from protein levels
were corroborated by RT-qPCR demonstrating the peak of
both mRNAs at 3 months and their decline in the cerebral
cortex of APP/PS1 mice at 6 and 9 months (Fig. 2h, i).
Next, we aimed to determine whether the absence of
Prnp modified tau expression in APP/PS1 mice. Triple
APP/PS1/Prnp0/0 Tg mice [69] showed a ~22 % increased
expression of tau at 9 months of age compared with non-Tg
APP/PS1/Prnp0/0 mice (Fig. 3a, b), in contrast to APP/PS1
expressing normal levels of PrPC with the same tau levels
(data not shown). Lastly, we performed a reduction of Prnp
by lentiviral vectors in APP/PS1-derived cultures (Fig. 3c).
Data revealed that decreased PrPC increased levels of en-
dogenous tau, similar to what happens with ADDL treat-
ment of Prnp0/0 neurons (see Fig. 3c, d). This reinforces
the notion that PrPC participates in the control of tau
expression in AD.
Next, we aimed to determine whether the induced tau
synthesis was regulated through the tau promoter. To this
end, we generate a triple transgenic mouse resulting from
crossing TgTP6.3 mouse, which overexpresses tau-GFP
under the β-actin promoter, with APP/PS1. Primary neu-
ronal cultures from embryos of these mice were treated
with siRNA-PrPC. In these cultured cells analyzed with
western blot, a band corresponding to endogenous tau and
the fusion protein tau-GFP could be detected at 55 and
95 kDa, respectively (Fig. 4). Revealed blots demonstrat-
ed an increase of both proteins (tau and tau-GFP) after
ADDL treatment, indicating that PrPC modulation of tau
expression in ADDL-treated neurons is not specific to the
tau promoter.
Correlative Progression of PrPC and Tau Expression
in Human AD Samples
Several studies have shown a decrease in PrPC levels in
different areas of AD-affected brains when compared with
controls [70, 71]. However these studies were focused on
advanced AD stages (from III to VI). In contrast, McNeill
and coworkers demonstrated increased levels of the PrPC in a
short duration case of AD [44]. Taking into account the
relation between levels of PrPC and tau protein reported in
APP/PS1mice and in vitro models, we analyzed levels of both
proteins at different stages. Developed films showed a mean
of ~46 % increase in total tau levels in AD (stage I) cases with
respect to healthy middle-aged individuals (Fig. 5a) and a
progressive decline in protein levels in accordance with the
increased PrPC expression (from 12 to 27 % between AD
stages I and III) (Fig. 5b, c).
Discussion
In this study, our experiments using Prnp0/0, Tg20, and
siRNA-lentivirus treatment support the notion that Prnp dos-
age does not influence total tau protein levels in cultured
cortical neurons. This reinforces previously reported microar-
ray data in N2a cells [65] and PrPC mutant mice at younger
stages compared with adults (2–3 months) [72–74]. However,
these observations are partially in contrast with some recently
published results, using human neuroblastoma [75] and
HEK293 cells [74]. In these studies, forced PrPC expression
in transfected cells with low expression levels of endogenous
PrPC decreased total tau protein levels [75].
It is relevant to note that increased expression of PrPC
increased its association with lipid rafts which may in turn
trigger increased intracellular oxidative stress [76, 22], thereby
affecting tau expression and phosphorylation [74, 77]. In
contrast to the expected result, decreased PrPC expression in
our experiments correlatedwith increased tau phosphorylation
(ptau/total tau as well as ptau/actin ratios) after in vitro treat-
ment with ADDLs. Thus, levels of tau, determined by tau 5
antibody, with or without γ-phosphatase treatment (to avoid
simultaneous detection of some ptau epitopes with tau 5
antibody), demonstrated that ADDL treatment is able to in-
duce a relevant increase in tau in the absence of PrPC as well
as in overexpressing cultures. In this sense, it is important to
note that both a lack of PrPC expression and overexpression of
the protein may impair PrPC function [73].
In addition, this is exclusively associated with ADDL
treatment since aggregated Aβ is unable to induce these
effects in treated neurons. In fact, aggregated peptides in
fibrillar forms failed to activate tau phosphorylation (e.g.,
tyr18 residue) in contrast to the antibody-mediated PrPC ag-
gregation in the membrane [37]. Thus, PrPC reduces the
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Fig. 2 a–d Immunohistochemical characterization of mouse brain sec-
tions. Anti-total tau antibody (monoclonal Tau 5) (a, b) and anti-PrPC
antibody (monoclonal 6H4) (c, d) were used to detect an increased
immunoreaction in APP/PS1 mice (n=4) (b, d) in contrast to wild-type
animals (n=4) (a, c). CA1 cornus ammonis I, CA2 cornus ammonis II,
DG dentate gyrus, GCL granular cell layer, H hilus,ML molecular layer,
SLM stratum lacunosum-moleculare, SO stratum oriens, SP stratum
pyramidale, SR stratum radiatum. Scale bar=200 μm. e Western blot
analysis of tau and PrPC in brains from wild-type (WT) and APP/PS1
mice (Tg) at different postnatal ages (3, 6, and 9 months, respectively).
Anti-actin monoclonal antibody was used for standardization. f, g Histo-
grams showing the densitometry study of each protein, tau (f) and PrPC
(g), respectively. h, i Histograms showing the RT-qPCR analysis of
expression of each protein, tau (h) and PrPC (i), respectively. Nine
animals were examined in each case, and bars represent the mean of
each group of transgenic animals normalized with control group at the
same age. *p<0.05, **p<0.01 (ANOVA test)
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effects of ADDLs in tau level modulation as well as their
phosphorylation. Schmitz et al. showed that increased PrPC
expression in transfected cells decreased ptau levels (deter-
mined using AT8 antibody) [74]. This was also observed in
Prnp0/0 mice (FVB background) with increased tau phosphor-
ylation at earlier stages [72]. Similar data have described tyr18
phosphorylation of tau after ADDL treatment [41]. Our data
confirm but also expand these observations to all the phospho-
epitopes studied. Concerning different phospho-epitopes, it
has been shown that, after Aβ oligomer treatment, wild-type
primary neurons increased specifically AT8-associated
phospho-epitopes as well as those recognized with 12E8
antibody (ser262/356) and 9G3 antibody (tyr18). In contrast,
ser396/404 (PHF1 antibody) remained unaltered (i.e, [78]). In
our experiments, the absence of Prnp increased the phosphor-
ylation of all ptau residues analyzed: (PHF1 antibody) ser396/
404, (AT8 antibody) ser202/thr205, and (phospho-thr181
antibody) thr181, in contrast to Prnp+/+ and Tg20 primary
cultures. In this respect, it has recently been shown that
thr181 and ser396 residues act as putative PrPC interacting
domains of tau [74]. Thus, it is reasonable to consider that
these residues were not phosphorylated by intracellular ki-
nases in wild-type and Tg20 cultures after ADDL treatment.
Several studies have analyzed the putative role of PrPC
expression in the survival of various models of neurodegen-
erative diseases (e.g., [79, 69]. In fact, PrPC seems not to play
a crucial role in survival in Parkinson, taupathies, or APP/PS1
mouse models [79, 69]. Although tau phosphorylation was
not analyzed, no differences were observed in the tangle levels
in the brain parenchyma of P301L mice with different Prnp
dosages [79]. Only one study describes in detail the propaga-
tion of tau pathology in the same mouse model [80]. In
contrast, the participation of PrPC in the appearance and
evolution of the hallmarks of AD (i.e., Aβ deposits) has been
reported by several laboratories [81, 82]. In fact, PrPC was
detected with immunohistochemistry close to Aβ deposits
[83] and accumulated in dystrophic neurites in AD postmor-
tem brain sections [84].
With respect to PrPC levels, most of these studies have been
focused on the changes of PrPC protein levels in advanced
stages of the disease (mainly stage III until VI) (i.e., [70])
probably due to neuronal loss [44]. In our study, we demon-
strated that in APP/PS1 mouse models, as well as in postmor-
tem AD brains (ranking from stage I to stage VI), there is an
Fig. 3 a, b Tau expression in
brains from triple transgenic mice
APP/PS1/Prnp0/0 (n=9)
compared to Prnp0/0 (n=9) at
9 months of age. An example of
western blot analysis of two
animals of each genotype (a) and
the respective histogram
quantification of tau expression
(b). Anti-actin monoclonal
antibody was used for
standardization. *p<0.05
(ANOVA test). c, d Cortical
cultures from APP/PS1 mice after
silencing PrPC expression with a
lentivirus (n=4). The western blot
analysis showed increased levels
of endogenous tau when PrPC
expression was decreased (c).
Densitometric analysis of
developed films (d). *p<0.05
(ANOVA test)
Fig. 4 Analysis of tau expression in cortical primary cultures from a
triple transgenic APP/PS1/TgTP6.3 mouse. Western blot analysis shows
an increase in tau expression when levels of PrPC are reduced with
lentiviral system. Both tau-GFP, which migrated to 95 KDa, and endog-
enous tau, around 55 KDa, are overexpressed. Anti-actin monoclonal
antibody was used for standardization. Densitometric values are standard-
ized with vehicle treatment, and quantification was represented as fold
increase±SEM of three independent experiments (n=10 cases)
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increase of PrPC protein in the brain at early stages of the
disease that peaks at around stage III in AD brains and at
~3 months old in APP/PS1 mice. Thereafter, PrPC levels
decreased inversely until the evolution of the clinical symp-
toms in both cases. Considering that low levels of PrPC may
increase tau expression, which may contribute to the AD
pathology, and that PrPC may act as an anti-oxidant agent as
has been widely demonstrated [85, 74], it is reasonable to
consider that overexpression of PrPC in AD might be part of a
protective response in the evolution of the disease.
PrPC Expression, ADDLs, Tau Phosphorylation,
and Neuroprotection
Phosphorylated form of tau protein is the main constituent of
NTFs in AD and its appearance correlates with neurodegen-
eration in the disease (see Braak and Braak (1991) [86] revised
in Avila (2010) [87]). It has been reported that the single
overexpression of human tau in a mouse model is robust
enough to induce tau phosphorylation [88] and neuronal ag-
gregation [89]. In fact, the expression of a truncated form of
tau reduces the excitotoxicity mediated by Aβ [90]. In our
study, the absence of PrPC in an APP/PS1 mouse and in
cultured APP/PS1-derived neurons led to increased tau levels.
It has been described how PrPC-Fyn complex is responsible
for pathological changes induced by ADDLs in tau phosphor-
ylation [41]. In this context, Fyn colocalizes with ser/thr
phosphorylated forms of tau in AD brains [91], and a direct
interaction between PrPC and Fyn has been described [92, 41].
Furthermore, Fyn is upregulated in AD brains and it interacts
with tau, phosphorylating it at tyr18 epitope [38], implicated in
the formation of tau aggregates and NFTs [93]. Along these
lines, we recently reported increased phosphorylation levels of
tyr18 in older (~9 months) but not younger (3–6 months) APP/
PS1 mice overexpressing PrPC [69]. The data presented more
recently by Larson et al., indicating a dependence of tyr18
phosphorylation on PrPC, reinforce our previously reported
data [41]. In addition, we also observed increased PrPC in
Tg20-derived cultures after ADDL treatment which may also
contribute to the increased levels of ptau (tyr18) observed in
our previous study [69] and the study by Larson et al. in 14-
month-old mice [41]. However, we were unable to determine
differences in ptau epitopes (other than tyr18) in old APP/PS1
mice with different PrPC dosages, although we did demon-
strate an increase in tau levels in APP/PS1 mice lacking PrPC
with respect to APP/PS1-Prnp+/+ as also reported by Larson
Fig. 5 Immunoblot analysis of hippocampal necropsies from AD pa-
tients compared to healthy (middle-aged adults) cases. a Example of
western blot determination of total tau levels and PrPC expression. Braak
and Braak stage progression is indicated (I–VI). Membranes were
retested with an antibody against actin for standardization. b Histograms
showing the densitometric study for all cases showed in Table 1. Asterisks
indicate significant differences between AD groups and healthy cases,
whose average represents the unit. *p<0.05, **p<0.01 (ANOVA test).
Increased levels of tau can be seen in patients from ADI to ADIII group
(a, b), and a correlative increment in PrPC expression is also shown (a, c)
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et al. [41]. In fact, our present results indicate that levels of
PrPC are largely reduced in APP/PS1 mice of 9 months of age
by 28 % (Fig. 2). This correlates with western blotting data in
human studies (see above). Taken together, these results
suggest that the control of tau expression by PrPC under
the effects of ADDLs declines along the development of
the disease or with age in the mouse model. This decline
correlates with increased appearance of NFTs enriched in
ptau in AD brains.
Are the Effects of PrPC Mediating Tau Levels
in ADDL-Treated Neurons Specific?
Our data indicate that tau levels are increased in the absence of
PrPC in the presence of ADDLs. In fact, it has been proposed
that PrPC suppresses tau transcription, probably though mod-
ulation of the Fyn pathway [75]. However, when we crossed
APP/PS1 mice with a mouse model of tau overexpression
under a β-actin promoter, reduction of PrPC levels by siRNA
induced increased presence of both endogenous (regulated by
tau promoter) and exogenous tau-GFP (regulated by β-actin
promoter) (Fig. 4). This might indicate that the absence of
PrPC also regulates the activity of different promoters or, more
likely, that PrPC may intervene in the aggregative state of the
protein or its turnover. In this sense, phosphorylation of tau
results in decreased tau degradation by the proteasomes that
appear to play a major role in the turnover of the protein [94].
Also, cortical neurons overexpressing tau alter intracellular
distribution of PrPC and promote accumulation in the cell
body, forming insoluble aggregates that in turn might damage
the proteasome [95]. Taken together, these data suggest de-
creased degradation of tau in some pathological cases and
probably modified synthesis/degradation rates. Further study
is warranted to examine these possibilities and to determine
biochemically whether PrPC modulates tau levels in both
healthy and AD-affected neurons.
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